Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology
Immunosuppressive drugs have been key to the success of liver transplantation and are essential components of the treatment of inflammatory bowel disease (IBD) and autoimmune hepatitis (AIH). For many but not all immunosuppressants, therapeutic drug monitoring (TDM) is recommended to guide therapy....
Gespeichert in:
| Veröffentlicht in: | Baillière's best practice & research. Clinical gastroenterology 2021-10, Vol.54-55, p.101756-101756, Article 101756 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 101756 |
|---|---|
| container_issue | |
| container_start_page | 101756 |
| container_title | Baillière's best practice & research. Clinical gastroenterology |
| container_volume | 54-55 |
| creator | Udomkarnjananun, Suwasin Francke, Marith I. De Winter, Brenda C.M. Mulder, Midas B. Baan, Carla C. Metselaar, Herold J. den Hoed, Caroline M. Hesselink, Dennis A. |
| description | Immunosuppressive drugs have been key to the success of liver transplantation and are essential components of the treatment of inflammatory bowel disease (IBD) and autoimmune hepatitis (AIH). For many but not all immunosuppressants, therapeutic drug monitoring (TDM) is recommended to guide therapy. In this article, the rationale and evidence for TDM of tacrolimus, mycophenolic acid, the mammalian target of rapamycin inhibitors, and azathioprine in liver transplantation, IBD, and AIH is reviewed. New developments, including algorithm-based/computer-assisted immunosuppressant dosing, measurement of immunosuppressants in alternative matrices for whole blood, and pharmacodynamic monitoring of these agents is discussed. It is expected that these novel techniques will be incorporate into the standard TDM in the next few years. |
| doi_str_mv | 10.1016/j.bpg.2021.101756 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2608132033</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1521691821000366</els_id><sourcerecordid>2608132033</sourcerecordid><originalsourceid>FETCH-LOGICAL-c467t-c7b6b67a163e31a1b48e91e922ba23b602f809ebcf773703b9b38c9b6a0024d3</originalsourceid><addsrcrecordid>eNp9kD1PwzAQhiMEEp8_gC0SC0uKz27tWEyo4kuqxNKFybKdS-qqsYOdIPXfk7RMDEw-n573dPdk2S2QGRDgD9uZ6ZoZJRSmv1jwk-wCFowWIIGfTjWFgksoz7PLlLaEjCEpL7LP9Qaj7nDonc2rODR5G7zrQ3S-yUOdu7YdfEhD10VMyX3jAUq58_kGO92HXWj2ufZV3ujUx4C-x3hoXmdntd4lvPl9r7L1y_N6-VasPl7fl0-rws656AsrDDdcaOAMGWgw8xIloKTUaMoMJ7QuiURjayGYIMxIw0orDdeE0HnFrrL749guhq8BU69alyzudtpjGJKinJTAKGFsRO_-oNswRD8uN1GCARMLMlJwpGwMKUWsVRddq-NeAVGTa7VVo2s1uVZH12Pm8ZjB8dBvh1El69BbrFxE26squH_SP2eih9E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2607313750</pqid></control><display><type>article</type><title>Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><creator>Udomkarnjananun, Suwasin ; Francke, Marith I. ; De Winter, Brenda C.M. ; Mulder, Midas B. ; Baan, Carla C. ; Metselaar, Herold J. ; den Hoed, Caroline M. ; Hesselink, Dennis A.</creator><creatorcontrib>Udomkarnjananun, Suwasin ; Francke, Marith I. ; De Winter, Brenda C.M. ; Mulder, Midas B. ; Baan, Carla C. ; Metselaar, Herold J. ; den Hoed, Caroline M. ; Hesselink, Dennis A.</creatorcontrib><description>Immunosuppressive drugs have been key to the success of liver transplantation and are essential components of the treatment of inflammatory bowel disease (IBD) and autoimmune hepatitis (AIH). For many but not all immunosuppressants, therapeutic drug monitoring (TDM) is recommended to guide therapy. In this article, the rationale and evidence for TDM of tacrolimus, mycophenolic acid, the mammalian target of rapamycin inhibitors, and azathioprine in liver transplantation, IBD, and AIH is reviewed. New developments, including algorithm-based/computer-assisted immunosuppressant dosing, measurement of immunosuppressants in alternative matrices for whole blood, and pharmacodynamic monitoring of these agents is discussed. It is expected that these novel techniques will be incorporate into the standard TDM in the next few years.</description><identifier>ISSN: 1521-6918</identifier><identifier>EISSN: 1532-1916</identifier><identifier>DOI: 10.1016/j.bpg.2021.101756</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Autoimmune hepatitis ; Bioavailability ; Biomarkers ; Clinical medicine ; Drug dosages ; Gene expression ; Immunosuppressants ; Immunosuppressive agents ; Inflammatory bowel disease ; Liver ; Metabolism ; Metabolites ; Patients ; Pharmacodynamics ; Pharmacokinetics ; Therapeutic drug monitoring ; Toxicity ; Transplantation ; Transplants & implants</subject><ispartof>Baillière's best practice & research. Clinical gastroenterology, 2021-10, Vol.54-55, p.101756-101756, Article 101756</ispartof><rights>2021 The Author(s)</rights><rights>2021. The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c467t-c7b6b67a163e31a1b48e91e922ba23b602f809ebcf773703b9b38c9b6a0024d3</citedby><cites>FETCH-LOGICAL-c467t-c7b6b67a163e31a1b48e91e922ba23b602f809ebcf773703b9b38c9b6a0024d3</cites><orcidid>0000-0002-0925-3771 ; 0000-0003-4087-9032 ; 0000-0003-3840-0213</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bpg.2021.101756$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids></links><search><creatorcontrib>Udomkarnjananun, Suwasin</creatorcontrib><creatorcontrib>Francke, Marith I.</creatorcontrib><creatorcontrib>De Winter, Brenda C.M.</creatorcontrib><creatorcontrib>Mulder, Midas B.</creatorcontrib><creatorcontrib>Baan, Carla C.</creatorcontrib><creatorcontrib>Metselaar, Herold J.</creatorcontrib><creatorcontrib>den Hoed, Caroline M.</creatorcontrib><creatorcontrib>Hesselink, Dennis A.</creatorcontrib><title>Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology</title><title>Baillière's best practice & research. Clinical gastroenterology</title><description>Immunosuppressive drugs have been key to the success of liver transplantation and are essential components of the treatment of inflammatory bowel disease (IBD) and autoimmune hepatitis (AIH). For many but not all immunosuppressants, therapeutic drug monitoring (TDM) is recommended to guide therapy. In this article, the rationale and evidence for TDM of tacrolimus, mycophenolic acid, the mammalian target of rapamycin inhibitors, and azathioprine in liver transplantation, IBD, and AIH is reviewed. New developments, including algorithm-based/computer-assisted immunosuppressant dosing, measurement of immunosuppressants in alternative matrices for whole blood, and pharmacodynamic monitoring of these agents is discussed. It is expected that these novel techniques will be incorporate into the standard TDM in the next few years.</description><subject>Autoimmune hepatitis</subject><subject>Bioavailability</subject><subject>Biomarkers</subject><subject>Clinical medicine</subject><subject>Drug dosages</subject><subject>Gene expression</subject><subject>Immunosuppressants</subject><subject>Immunosuppressive agents</subject><subject>Inflammatory bowel disease</subject><subject>Liver</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Patients</subject><subject>Pharmacodynamics</subject><subject>Pharmacokinetics</subject><subject>Therapeutic drug monitoring</subject><subject>Toxicity</subject><subject>Transplantation</subject><subject>Transplants & implants</subject><issn>1521-6918</issn><issn>1532-1916</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kD1PwzAQhiMEEp8_gC0SC0uKz27tWEyo4kuqxNKFybKdS-qqsYOdIPXfk7RMDEw-n573dPdk2S2QGRDgD9uZ6ZoZJRSmv1jwk-wCFowWIIGfTjWFgksoz7PLlLaEjCEpL7LP9Qaj7nDonc2rODR5G7zrQ3S-yUOdu7YdfEhD10VMyX3jAUq58_kGO92HXWj2ufZV3ujUx4C-x3hoXmdntd4lvPl9r7L1y_N6-VasPl7fl0-rws656AsrDDdcaOAMGWgw8xIloKTUaMoMJ7QuiURjayGYIMxIw0orDdeE0HnFrrL749guhq8BU69alyzudtpjGJKinJTAKGFsRO_-oNswRD8uN1GCARMLMlJwpGwMKUWsVRddq-NeAVGTa7VVo2s1uVZH12Pm8ZjB8dBvh1El69BbrFxE26squH_SP2eih9E</recordid><startdate>202110</startdate><enddate>202110</enddate><creator>Udomkarnjananun, Suwasin</creator><creator>Francke, Marith I.</creator><creator>De Winter, Brenda C.M.</creator><creator>Mulder, Midas B.</creator><creator>Baan, Carla C.</creator><creator>Metselaar, Herold J.</creator><creator>den Hoed, Caroline M.</creator><creator>Hesselink, Dennis A.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0925-3771</orcidid><orcidid>https://orcid.org/0000-0003-4087-9032</orcidid><orcidid>https://orcid.org/0000-0003-3840-0213</orcidid></search><sort><creationdate>202110</creationdate><title>Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology</title><author>Udomkarnjananun, Suwasin ; Francke, Marith I. ; De Winter, Brenda C.M. ; Mulder, Midas B. ; Baan, Carla C. ; Metselaar, Herold J. ; den Hoed, Caroline M. ; Hesselink, Dennis A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c467t-c7b6b67a163e31a1b48e91e922ba23b602f809ebcf773703b9b38c9b6a0024d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Autoimmune hepatitis</topic><topic>Bioavailability</topic><topic>Biomarkers</topic><topic>Clinical medicine</topic><topic>Drug dosages</topic><topic>Gene expression</topic><topic>Immunosuppressants</topic><topic>Immunosuppressive agents</topic><topic>Inflammatory bowel disease</topic><topic>Liver</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Patients</topic><topic>Pharmacodynamics</topic><topic>Pharmacokinetics</topic><topic>Therapeutic drug monitoring</topic><topic>Toxicity</topic><topic>Transplantation</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Udomkarnjananun, Suwasin</creatorcontrib><creatorcontrib>Francke, Marith I.</creatorcontrib><creatorcontrib>De Winter, Brenda C.M.</creatorcontrib><creatorcontrib>Mulder, Midas B.</creatorcontrib><creatorcontrib>Baan, Carla C.</creatorcontrib><creatorcontrib>Metselaar, Herold J.</creatorcontrib><creatorcontrib>den Hoed, Caroline M.</creatorcontrib><creatorcontrib>Hesselink, Dennis A.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Baillière's best practice & research. Clinical gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Udomkarnjananun, Suwasin</au><au>Francke, Marith I.</au><au>De Winter, Brenda C.M.</au><au>Mulder, Midas B.</au><au>Baan, Carla C.</au><au>Metselaar, Herold J.</au><au>den Hoed, Caroline M.</au><au>Hesselink, Dennis A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology</atitle><jtitle>Baillière's best practice & research. Clinical gastroenterology</jtitle><date>2021-10</date><risdate>2021</risdate><volume>54-55</volume><spage>101756</spage><epage>101756</epage><pages>101756-101756</pages><artnum>101756</artnum><issn>1521-6918</issn><eissn>1532-1916</eissn><abstract>Immunosuppressive drugs have been key to the success of liver transplantation and are essential components of the treatment of inflammatory bowel disease (IBD) and autoimmune hepatitis (AIH). For many but not all immunosuppressants, therapeutic drug monitoring (TDM) is recommended to guide therapy. In this article, the rationale and evidence for TDM of tacrolimus, mycophenolic acid, the mammalian target of rapamycin inhibitors, and azathioprine in liver transplantation, IBD, and AIH is reviewed. New developments, including algorithm-based/computer-assisted immunosuppressant dosing, measurement of immunosuppressants in alternative matrices for whole blood, and pharmacodynamic monitoring of these agents is discussed. It is expected that these novel techniques will be incorporate into the standard TDM in the next few years.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><doi>10.1016/j.bpg.2021.101756</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-0925-3771</orcidid><orcidid>https://orcid.org/0000-0003-4087-9032</orcidid><orcidid>https://orcid.org/0000-0003-3840-0213</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1521-6918 |
| ispartof | Baillière's best practice & research. Clinical gastroenterology, 2021-10, Vol.54-55, p.101756-101756, Article 101756 |
| issn | 1521-6918 1532-1916 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2608132033 |
| source | Elsevier ScienceDirect Journals Complete - AutoHoldings |
| subjects | Autoimmune hepatitis Bioavailability Biomarkers Clinical medicine Drug dosages Gene expression Immunosuppressants Immunosuppressive agents Inflammatory bowel disease Liver Metabolism Metabolites Patients Pharmacodynamics Pharmacokinetics Therapeutic drug monitoring Toxicity Transplantation Transplants & implants |
| title | Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T09%3A27%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapeutic%20drug%20monitoring%20of%20immunosuppressive%20drugs%20in%20hepatology%20and%20gastroenterology&rft.jtitle=Bailli%C3%A8re's%20best%20practice%20&%20research.%20Clinical%20gastroenterology&rft.au=Udomkarnjananun,%20Suwasin&rft.date=2021-10&rft.volume=54-55&rft.spage=101756&rft.epage=101756&rft.pages=101756-101756&rft.artnum=101756&rft.issn=1521-6918&rft.eissn=1532-1916&rft_id=info:doi/10.1016/j.bpg.2021.101756&rft_dat=%3Cproquest_cross%3E2608132033%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2607313750&rft_id=info:pmid/&rft_els_id=S1521691821000366&rfr_iscdi=true |